Anti-angiogenic peptides from the N-terminus of endostatin

US7524811B2 · kind B2 · utility

Assignee

• Children's Medical Center Corporation · US

Inventors

• Judah Folkman · Brookline, US
• Kashi Javaherian · Heidelberg, DE
• Robert Tjin Tham Sjin · Framingham, US

Key dates

• Filing date: Feb 28, 2006
• Grant date: Apr 28, 2009
• Expiry date: Feb 28, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.